Randomised trial of the P2X₃ receptor antagonist sivopixant for refractory chronic cough.

ABSTRACT:

Background

The purinoceptor subtype P2X₃ has been shown to have significant involvement in the cough reflex; the heterotrimer version of the purinoceptor (P2X_2/3) has been implicated in taste disturbance. The most advanced clinical candidate antagonist gefapixant has low selectivity among P2X₃ receptors and induced taste disturbance, whereas newly developed sivopixant has high selectivity towards P2X₃ versus P2X_2/3.

Methods

In a phase 2a, randomised, double-blind, placebo-controlled, crossover, multicentre study, adult patients with refractory or unexplained chronic cough received oral sivopixant 150 mg or placebo once daily for 2 weeks, followed by a 2-3-week washout period, and then crossed over to placebo or si

SUBMITTER: Niimi A 

PROVIDER: S-EPMC9176336 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature